The UPR-CTU has been on the forefront of the HIV/AIDS clinical research in the island of Puerto Rico and has the longest experience with participation on observational studies, perinatal interventions, clinical and behavior intervention and more recently prevention trials and studies. The Integrated University of Puerto Rico Clinical Trials Unit (UPR-CTU/60446) is a coalition/merger of the three previous independent Clinical Trials Sites associated to the ACTG, HVTN and PACTG research Networks. The UPR-CTU, has 3 Clinical Research Sites which have worked with the Leadership Networks established to further advance the high priority areas relating to: adult HIV therapeutic strategies, including HIV cure, noninfectious comorbidities, and the infectious comorbidities of hepatitis and tuberculosis; strategies to address HIV and HIV-associated infections in pediatric and maternal populations and vaccines to prevent HIV infections. We have also carried out studies sponsored by other networks (MTN, ATN, and HPTN) that target integrated HIV prevention strategies and microbicide strategies to prevent HIV infections. With this proposal we will further integrate the functions of the UPR-CTU by establishing nine (9) divisions that will constitute the centralized operations arm of the UPR-CTU: Administration and Financial Affairs. Clinical Staff and Investigators (funded with PIF); Pharmacy, Coordination and Training, Central Laboratory, Data Coordination, Regulatory Affairs, Quality Management/Evaluations and Community Engagement in order to improve the efficacy and utilization of resources. We will conduct research in following six research areas: 1) Adult HIV therapeutic strategies, including HIV cure, noninfectious comorbidities, and the infectious comorbidities of hepatitis and tuberculosis; 2) Strategies to address HIV and HIV-associated infections in pediatric and maternal populations; 3) Integrated HIV prevention strategies; 4) Microbicide strategies to prevent HIV infections; and 5) Vaccines to prevent HIV infections. Among the significant aspects of this proposal are the topics of interest and research, the availability of diverse groups of interest such as: people living with HIV, populations with diverse degrees of risk for HIV, populations with specific characteristics or risk behaviors (MSM, commercial sex workers, LGBTT, IDUs, adolescents, women and children) and the experience and diversity of disciplines integrated into this CTU.

Public Health Relevance

The Integrated University of Puerto Rico Clinical Trials Unit will provide access to clinical, behavior and prevention trials to a large number of participants of Hispanic ethnicity located in Puerto Rico contributing to the research agenda in areas relating to: adult HIV therapeutic strategies, comorbidities; strategies to address HIV and HIV-associated infections in pediatric and maternal populations and vaccines to prevent HIV infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069415-14
Application #
9605059
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Pouliot, Eileen M
Project Start
2007-02-01
Project End
2020-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
14
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Puerto Rico Med Sciences
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
948108063
City
San Juan
State
PR
Country
United States
Zip Code
00936
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Utay, Netanya S; Kitch, Douglas W; Yeh, Eunice et al. (2018) Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone. J Infect Dis 217:1770-1781
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Taiwo, Babafemi O; Zheng, Lu; Stefanescu, Andrei et al. (2018) ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Clin Infect Dis 66:1689-1697
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Gandhi, Monica; Gandhi, Rajesh T; Stefanescu, Andrei et al. (2018) Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. J Infect Dis 218:234-238
Cranston, Ross D; Cespedes, Michelle S; Paczuski, Pawel et al. (2018) High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298. Sex Transm Dis 45:266-271
Iribarren, Sarah J; Ghazzawi, Alhasan; Sheinfil, Alan Z et al. (2018) Mixed-Method Evaluation of Social Media-Based Tools and Traditional Strategies to Recruit High-Risk and Hard-to-Reach Populations into an HIV Prevention Intervention Study. AIDS Behav 22:347-357
Nixon, Daniel E; Bosch, Ronald J; Chan, Ellen S et al. (2017) Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A52 J Clin Lipidol 11:61-69

Showing the most recent 10 out of 108 publications